NCT00532961View on ClinicalTrials.gov

Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex

PHASE4CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2005

Study Completion Date

June 30, 2005

Conditions
Inflammation
Interventions
DRUG

Loteprednol etabonate 0.5% and tobramycin 0.3%

ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days

DRUG

Dexamethasone 0.1% and tobramycin 0.3%

ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT00532961 - Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex | Biotech Hunter | Biotech Hunter